---
schema_version: "secwatch.filing_event.v1"
accession: "0001520138-22-000392"
form_type: "8-K/A"
ticker: "BIVI"
cik: "0001580149"
company_name: "BIOVIE INC."
filed_at: "2022-09-07T23:59:59+00:00"
generated_at: "2026-06-23T14:09:48.830366+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioVie announces Phase 2 Alzheimer's results for NE3107 with cognitive and biomarker improvements

## Summary
- 82% of 17 mild AD patients showed 2.6-point decrease in ADAS-Cog12 (p=0.046) after 3 months of NE3107.
- NE3107 significantly reduced TNF-alpha; improvements in cognition correlated with TNF reduction (R=0.70, p=0.0077).
- Phase 3 AD trial (NCT04669028) half enrolled; topline data expected mid-2023, subject to DSMB review.
- Phase 2 Parkinson's trial (NCT05083260) enrolling; data readout by end of 2022; early efficacy signal detected.
- Phase 2b BIV201 trial for ascites delayed by COVID; data readout anticipated mid-2023.

## SEC filing metadata
- accession: 0001520138-22-000392
- form_type: 8-K/A
- ticker: BIVI
- cik: 0001580149
- company_name: BIOVIE INC.
- filed_at: 2022-09-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 9.01, 7.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1580149/000152013822000392/0001520138-22-000392-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1580149/000152013822000392/bivi-20220907_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001520138-22-000392
- JSON: https://secwatch.observer/filing/0001520138-22-000392.json
- Plain text: https://secwatch.observer/filing/0001520138-22-000392.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.